Thomas Moll

US Patent:

20050276756, Dec 15, 2005

Filed:

Mar 22, 2005

Appl. No.:

11/087177

Inventors:

William Hoo - Carlsbad CA, US
Eric Jensen - San Diego CA, US
Thomas Moll - San Diego CA, US
Dennis Carlo - Rancho Santa Fe CA, US
Brian Helmich - La Jolla CA, US
Soonpin Yei - Carlsbad CA, US
Jayant Thatte - San Diego CA, US

International Classification:

A61K051/00
A61K039/395
A61K035/78
A61K033/24
A61K031/704
A61K031/7048
A61K031/7076

US Classification:

424001490, 424143100, 424236100, 514034000, 514050000, 514027000, 514039000, 424649000, 424731000, 514251000, 514410000

Abstract:

The invention provides compositions containing an antigen and a TIM targeting molecule. The invention additionally provides a TIM targeting molecule conjugate, for example, a TIM targeting molecule targeted to a therapeutic or diagnostic moiety. The invention additionally provides methods of using such compositions. In one embodiment, the invention provides a method of stimulating an immune response in an individual by administering a composition comprising an antigen and a TIM targeting molecule in a pharmaceutically acceptable carrier. In another embodiment, the invention provides a method of stimulating an immune response in an individual by administering an antigen and a TIM targeting molecule, which can be administered together in a single composition or separately.

US Patent:

20060057102, Mar 16, 2006

Filed:

Aug 11, 2005

Appl. No.:

11/202287

Inventors:

Xin Zheng - Wellesley MA, US
Terry Strom - Brookline MA, US
Thomas Moll - San Diego CA, US

International Classification:

A61K 38/20

US Classification:

424085200

Abstract:

The invention features methods of treating patients who have received, or who are scheduled to receive, a heart, lung, or heart-lung transplant by administering to the patient an agent that antagonizes IL-15 or the IL-15 receptor (IL-15R).

US Patent:

20060057680, Mar 16, 2006

Filed:

Aug 11, 2005

Appl. No.:

11/201585

Inventors:

Xin Zheng - Wellesley MA, US
Terry Strom - Brookline MA, US
Thomas Moll - San Diego CA, US

International Classification:

C07K 14/54
C07H 21/04
C12P 21/04

US Classification:

435069520, 435320100, 435325000, 530351000, 536023500

Abstract:

Mutant IL-15 polypeptides and compositions including the polypeptides are described herein. In various embodiments, a mutant IL-15 polypeptide is joined to a heterologous polypeptide. Also described herein are uses of the mutant IL-15 polypeptides, e.g., in suppressing immune responses.

US Patent:

20060236411, Oct 19, 2006

Filed:

Oct 13, 2003

Appl. No.:

10/530987

Inventors:

Ingeborg Dreher - Mannheim, DE
Thomas Moll - San Diego CA, US

International Classification:

A01K 67/027
C07H 21/04
C12P 21/04
C07K 14/54
C07K 16/46
C12N 5/06

US Classification:

800014000, 530351000, 530391100, 435069700, 435320100, 435328000, 536023530

Abstract:

The invention relates to fusion proteins consisting of a wild-type IL-15 and a IgG-Fc fragment, apart from a mouse IgG2b fragment, nucleic acids encoding said proteins, vectors, modified cells, and also to the use thereof for preparing drugs which are used, for example for preventing and/or curing disorders resulting from a transplantation and/or autoimmune diseases.

US Patent:

20090117618, May 7, 2009

Filed:

Apr 13, 2005

Appl. No.:

10/592010

Inventors:

Andreas Herrmann - Koeln, DE
Ingeborg Dreher - Mannheim, DE
Thomas Moll - San Diego CA, US
Stefanie Zahn - Essen, DE

International Classification:

C07H 21/00
C12N 1/00
C12N 5/00
C12P 21/00
C12N 15/00

US Classification:

435 6952, 536 241, 435243, 435325, 435455

Abstract:

The invention relates to an expression system containing one or more nucleic acid(s) comprising at least one nucleic acid for an interleukin 15/Fc (IL-15/Fc) fusion protein, at least one promotor, at least one nucleic acid for a CD5 leader and, where appropriate, at least one nucleic acid for a selectable marker gene; to a nucleic acid comprising the components of the said expression system and to a host cell containing the expression system or the nucleic acid. Furthermore, the invention relates to a process for preparing an IL-15/Fc fusion protein, using the expression system, and to the use of the expression system, the nucleic acid, the host cell or the CD5 leader for expression in host cells.

US Patent:

20210290857, Sep 23, 2021

Filed:

Jun 7, 2021

Appl. No.:

17/340977

Inventors:

- San Diego CA, US
Karen K. Daniels - San Diego CA, US
Thomas Moll - San Diego CA, US
Ronald B. Moss - San Diego CA, US
Dennis J. Carlo - San Diego CA, US

International Classification:

A61M 5/315
A61K 31/485

Abstract:

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose. Also provided herein are compositions and methods of treating opioid overdose using high dose naloxone.

US Patent:

20200121859, Apr 23, 2020

Filed:

Oct 3, 2019

Appl. No.:

16/592319

Inventors:

- San Diego CA, US
Karen K. Daniels - San Diego CA, US
Thomas Moll - San Diego CA, US
Ronald B. Moss - San Diego CA, US
Dennis J. Carlo - San Diego CA, US

International Classification:

A61M 5/315
A61K 31/485

Abstract:

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose. Also provided herein are compositions and methods of treating opioid overdose using high dose naloxone.

US Patent:

20190358403, Nov 28, 2019

Filed:

May 24, 2019

Appl. No.:

16/422639

Inventors:

- San Diego CA, US
Karen K. Daniels - San Diego CA, US
Thomas Moll - San Diego CA, US

International Classification:

A61M 5/28
A61M 5/20
A61K 31/485

Abstract:

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose.